Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On March 24, 2021, the Board of Directors (the "Board") of Eloxx
Pharmaceuticals, Inc. (the "Company") accepted the resignation of Mr. Stephen
MacDonald as Vice President, Finance and Accounting, and Treasurer, effective
March 26, 2021.
Gary D. Rakers, 37, who joined with the Company in January 2020 and previously
served as as Corporate Controller and Assistant Treasurer, was promoted to
Executive Director, Finance and Accounting and Corporate Controller. The Board
appointed Mr. Rakers principal financial and accounting officer and Treasurer
effective March 26, 2021. Mr. Rakers receives a base annual salary of $250,000,
a target bonus of 28% and was granted 16,000 options to purchase common stock of
the Company at an exercise price equal to the fair market value of the Company's
common stock on the date of his promotion. Prior to joining the Company, Mr.
Rakers spent 6 years with Tesaro, Inc., prior to its acquisition by GSK, where
he held positions of increasing responsibility, culminating in the role of
Associate Director of Technical Accounting and Operations. Previously, Mr.
Rakers spent 8 years in the audit and assurance practice of Deloitte & Touche
LLP, with a focus on the healthcare and life sciences sector. Mr. Rakers will
report to the Chief Executive Officer or his designee.
© Edgar Online, source Glimpses
ELOXX PHARMACEUTICALS, INC. 
